Novel Drugs
|
Names |
Mechanism |
Indication |
| Ibrexafungerp (Brexafemme®) | for adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC). | |
|
Vericiguat (Verquvo®) |
Soluble guanylate cyclase (sGC) stimulator |
following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and EF < 45% (2021-Jan @FDA) |
|
Voclosporin (Lupkynis®) |
Calcineurin inhibitor |
Adults with active lupus nephritis (2021-Jan @FDA) |
